Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 59 |
| Updated: | 4/17/2018 |
| Start Date: | April 22, 1999 |
| End Date: | January 2019 |
High-Dose Infusional Taxol, Amifostine, Doxorubicin, and Cyclophosphamide Followed by Stem Cell Rescue for High Risk Primary and Responsive Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation
may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
Amifostine may protect normal cells from the side effects of chemotherapy.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, amifostine,
and peripheral stem cell transplantation in treating patients who have stage II, stage III,
or stage IV breast cancer.
they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation
may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
Amifostine may protect normal cells from the side effects of chemotherapy.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, amifostine,
and peripheral stem cell transplantation in treating patients who have stage II, stage III,
or stage IV breast cancer.
OBJECTIVES: I. Evaluate the feasibility of high dose doxorubicin, cyclophosphamide,
paclitaxel, and amifostine in patients with high risk stage II/III and responsive stage IV
advanced breast cancer. II. Determine the pharmacokinetic profile of paclitaxel administered
with amifostine in this regimen in these patients. III. Assess the toxicity of this treatment
regimen in this patient population.
OUTLINE: Patients receive filgrastim (G-CSF) subcutaneously twice daily on days 1-4 for
peripheral blood stem cell (PBSC) mobilization and continuing through days 5-10 during PBSC
collection. At least 2 weeks following mobilization, patients receive doxorubicin IV as a
continuous infusion on days -9 through -5 followed by cyclophosphamide IV over 2 hours on day
-5 and amifostine IV over 15 minutes, and paclitaxel IV over 24 hours on day -4. On day -2,
25% PBSC are reinfused and 75% are reinfused on day 0, followed by daily G-CSF subcutaneously
or IV beginning on day 1. Patients are followed every 3 months for 2 years, then periodically
thereafter.
PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study within 6-8 months.
paclitaxel, and amifostine in patients with high risk stage II/III and responsive stage IV
advanced breast cancer. II. Determine the pharmacokinetic profile of paclitaxel administered
with amifostine in this regimen in these patients. III. Assess the toxicity of this treatment
regimen in this patient population.
OUTLINE: Patients receive filgrastim (G-CSF) subcutaneously twice daily on days 1-4 for
peripheral blood stem cell (PBSC) mobilization and continuing through days 5-10 during PBSC
collection. At least 2 weeks following mobilization, patients receive doxorubicin IV as a
continuous infusion on days -9 through -5 followed by cyclophosphamide IV over 2 hours on day
-5 and amifostine IV over 15 minutes, and paclitaxel IV over 24 hours on day -4. On day -2,
25% PBSC are reinfused and 75% are reinfused on day 0, followed by daily G-CSF subcutaneously
or IV beginning on day 1. Patients are followed every 3 months for 2 years, then periodically
thereafter.
PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study within 6-8 months.
DISEASE CHARACTERISTICS: Histologically proven breast cancer including: Stage IV metastatic
disease with current partial or complete response to prior induction chemotherapy High risk
primary disease with less than 60% chance of progression free survival at 3 years Stage II
tumors with 10 or more axillary node involvement Stage IIIA or IIIB tumors No bone marrow
metastases No CNS metastases No more than 10 bone metastases Hormone receptor status: Not
specified
PATIENT CHARACTERISTICS: Age: 59 and under Menopausal status: Not specified Performance
status: Karnofsky 80-100% Life expectancy: Not specified Hematopoietic: Neutrophil count
greater than 2,000/mm3 Platelet count greater than 150,000/mm3 Hemoglobin greater than 9
g/dL (blood transfusions allowed) Hepatic: Bilirubin no greater than 1.2 mg/dL SGOT or SGPT
less than 1.5 times upper limit of normal Renal: Creatinine no greater than 1.2 mg/dL
Creatinine clearance at least 80 mL/min No prior hemorrhagic cystitis Cardiovascular:
Ejection fraction at least 55% by MUGA No prior valvular heart disease or arrhythmia
Pulmonary: DLCO at least 60% lower limit of predicted pCO2 no greater than 43 mmHg on room
air pO2 greater than 85 mmHg on room air FEV 1 at least 2 liters Other: No other prior
malignancy except basal or squamous cell skin cancer, or carcinoma in situ or stage I
carcinoma of the cervix Not pregnant HIV negative Hepatitis B negative No prior history of
disabling psychosocial disorder No other CNS dysfunction
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics At least 4 weeks since prior chemotherapy No more than 2 prior chemotherapy
regimens for metastatic disease Prior total doxorubicin dose no greater than 180 mg/m2
Prior total paclitaxel dose no greater than 750 mg/m2 Endocrine therapy: At least 4 weeks
since prior hormonal therapy Radiotherapy: At least 4 weeks since prior radiotherapy No
prior radiotherapy to the left chest wall No prior radiotherapy to greater than 20% of bone
marrow (excluding syngeneic transplantation candidates) Surgery: Not specified
We found this trial at
1
site
Click here to add this to my saved trials
